Details of the Drug

General Information of Drug (ID: DMD9WSC)

Drug Name
Memantine
Synonyms Memantine ER; Namenda XR; Memantine (extended release); Memantine (extended release), Forest
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Approved [1]
Asperger syndrome N.A. Approved [2]
Glioblastoma 2A00 Approved [2]
Affected Organisms
Humans and other mammals
ATC Code
N06DX01: Memantine
N06DX: Other anti-dementia drugs
N06D: ANTI-DEMENTIA DRUGS
N06: PSYCHOANALEPTICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 179.3
Logarithm of the Partition Coefficient (xlogp) 3.3
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 1
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3-7 h []
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
Approximately 48% of administered memantine is excreted unchanged in urine []
Half-life
The concentration or amount of drug in body reduced by one-half in 60 - 100 hours []
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.324 micromolar/kg/day [5]
Vd
The volume of distribution (Vd) of drug is 9-11 L/kg []
Chemical Identifiers
Formula
C12H21N
IUPAC Name
3,5-dimethyladamantan-1-amine
Canonical SMILES
CC12CC3CC(C1)(CC(C3)(C2)N)C
InChI
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
InChIKey
BUGYDGFZZOZRHP-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4054
ChEBI ID
CHEMBL807
CAS Number
19982-08-2
UNII
W8O17SJF3T
DrugBank ID
DB01043
TTD ID
D01JEU
VARIDT ID
DR00023
INTEDE ID
DR2292
ACDINA ID
D00395
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [8]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Gene/Protein Processing [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Memantine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Memantine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Memantine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Memantine and Desipramine. Attention deficit hyperactivity disorder [6A05] [10]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Memantine and Cariprazine. Bipolar disorder [6A60] [10]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Memantine and OPC-34712. Depression [6A70-6A7Z] [10]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Memantine and Clomipramine. Depression [6A70-6A7Z] [10]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Memantine and Doxepin. Depression [6A70-6A7Z] [10]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Memantine and Mepenzolate. Digestive system disease [DE2Z] [10]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Memantine and Oxybutynine. Discovery agent [N.A.] [10]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Memantine and Diphenhydramine. Episodic vestibular syndrome [AB31] [10]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Memantine and Solifenacin. Functional bladder disorder [GC50] [10]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Memantine and Belladonna. Infectious gastroenteritis/colitis [1A40] [10]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Memantine and ITI-007. Insomnia [7A00-7A0Z] [10]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Memantine and Phenindamine. Nasopharyngitis [CA00] [10]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Memantine and Promethazine. Nausea/vomiting [MD90] [10]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Memantine and Cyclizine. Nausea/vomiting [MD90] [10]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Memantine and Flavoxate. Pain [MG30-MG3Z] [10]
Pergolide DM14MAE Minor Additive dopaminergic effects by the combination of Memantine and Pergolide. Parkinsonism [8A00] [11]
Opicapone DM1BKA6 Minor Additive dopaminergic effects by the combination of Memantine and Opicapone. Parkinsonism [8A00] [11]
Levodopa DMN3E57 Minor Additive dopaminergic effects by the combination of Memantine and Levodopa. Parkinsonism [8A00] [11]
Bromocriptine DMVE3TK Minor Additive dopaminergic effects by the combination of Memantine and Bromocriptine. Parkinsonism [8A00] [11]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Memantine and Orphenadrine. Parkinsonism [8A00] [10]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Memantine and Methylscopolamine. Peptic ulcer [DA61] [10]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Memantine and Levomepromazine. Psychotic disorder [6A20-6A25] [10]
Neupro DMHEAB1 Minor Additive dopaminergic effects by the combination of Memantine and Neupro. Restless legs syndrome [7A80] [11]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Memantine and Quetiapine. Schizophrenia [6A20] [10]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Memantine and Aripiprazole. Schizophrenia [6A20] [10]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Memantine and Iloperidone. Schizophrenia [6A20] [10]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Memantine and Paliperidone. Schizophrenia [6A20] [10]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Memantine and Molindone. Schizophrenia [6A20] [10]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Memantine and Thiothixene. Schizophrenia [6A20] [10]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Memantine and Asenapine. Schizophrenia [6A20] [10]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Memantine and Pimozide. Schizophrenia [6A20] [10]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Memantine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [10]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Memantine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [9]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Memantine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [10]
⏷ Show the Full List of 36 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium stearyl fumarate E00545 23665634 lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Memantine 5 mg tablet 5 mg Oral Tablet Oral
Memantine 10 mg tablet 10 mg Oral Tablet Oral
Memantine 14 mg capsule 14 mg 24 HR Extended Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4253).
2 Memantine FDA Label
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32.
7 Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52.
8 Memantine induces apoptosis and inhibits cell cycle progression in LNCaP prostate cancer cells. Hum Exp Toxicol. 2018 Sep;37(9):953-958. doi: 10.1177/0960327117747025. Epub 2017 Dec 11.
9 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
10 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".